Evommune, Inc.
NYSE:EVMNBiotechnology
-$0.17 today
- Market cap
- $284.49M
- Beta
- 0.10
- P/E (TTM)
- -9.1
- EPS (TTM)
- -$2.26
Volume 0.60M
Average 0.38M
EVMN Gross Profit
Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.
Evommune, Inc.NYSE: EVMN
Gross Profit · Q1 FY2026 · quarter ended Mar 2026
Gross profit turns negative
Q1 FY2026 gross profit was -$349K, compared with $2.62M a year earlier. Trailing-twelve-month gross profit was $9.28M.
Context
- Gross profit amounted to 100.0% of revenue in FY2025, up 18.4 pp from a year earlier.
- Gross profit increased in 2 of the last 2 fiscal years.
- FY2025 was the highest annual figure in the 3 fiscal years shown.
What to watch
Whether quarterly gross profit holds near -$349K or moves back toward the trailing-twelve-month quarterly average of $2.32M.
Sources:Income StatementText generated from reported figures; not investment advice.
Gross Profit history
USD · from the income statement
- Latest · FY2025
- 13M USD
- Year-over-year change
- +127.6%
- 2-year CAGR
- +80.3%
| Period | Period end | Gross Profit | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 13M | +127.6% |
| FY2024 | 2024-12-31 | 5.71M | +42.8% |
| FY2023 | 2023-12-31 | 4M | — |
Gross Profit vs competitors
How EVMN compares with its peers on the latest reported figures
- EVMN's LTM Mar 2026 gross profit of $9.28M is the 7th highest of the 10 companies compared; the peer median is $65.55M.
- Gross profit amounts to 92.8% of revenue for EVMN, versus a peer median of 76.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
FTREFortrea Holdings Inc. | LTM Jun 2026 | $457.9M | -11.9% | -16.2% | 17.1% |
| LTM Jun 2026 | $286.42M | +74.1% | +22.2% | 98.6% | |
| LTM Sep 2026 | $182.57M | +35.8% | -36.4% | 68.6% | |
| LTM Mar 2026 | $145.11M | +6.2% | -2.6% | 96.0% | |
| LTM Mar 2026 | $65.55M | +83.9% | -15.3% | 83.9% | |
| LTM Mar 2026 | $10.25M | -61.7% | — | 35.5% | |
EVMNEvommune, Inc. | LTM Mar 2026 | $9.28M | — | — | 92.8% |
| LTM Mar 2026 | $5.83M | -88.9% | -4.0% | 76.5% | |
CLYMClimb Bio, Inc. | LTM Mar 2026 | -$106K | — | — | — |
ARTVArtiva Biotherapeutics, Inc. | LTM Mar 2026 | -$666K | — | — | — |
| Peer median (excluding EVMN) | $65.55M | +6.2% | -9.6% | 76.5% | |
Competitors are the stored peer set for EVMN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|
| Revenue | 5M | 7M | 13M |
| Cost of Revenue | 1M | 1.29M | 0 |
| Gross Profit | 4M | 5.71M | 13M |
| Gross Margin | 80.0% | 81.6% | 100.0% |
| Research & Development | 32M | 64.24M | 74.04M |
| Selling, General & Admin | 9.85M | 11.48M | 20.03M |
| Operating Expenses | 41.85M | 75.73M | 94.07M |
| Depreciation & Amortization | 1M | 1.29M | 1.39M |
| EBITDA | (33M) | (65.49M) | (67.48M) |
| EBITDA Margin | -659.9% | -935.5% | -519.1% |
| Operating Income | (37.85M) | (70.01M) | (81.07M) |
| Operating Margin | -757.0% | -1000.2% | -623.6% |
| Interest Income | 3.86M | 3.24M | 3.32M |
| Interest Expense | 58K | 34K | 0 |
| Other Income / Expenses | 3.8M | 3.2M | 12.2M |
| Income Before Tax | (34.05M) | (66.81M) | (68.87M) |
| Pre-Tax Margin | -681.1% | -954.4% | -529.8% |
| Income Tax Expense | 0 | 0 | 0 |
| Net Income | (34.05M) | (66.81M) | (68.87M) |
| Net Margin | -681.1% | -954.4% | -529.8% |
| EPS (Basic) | (1.13) | (2.27) | (2.18) |
| EPS (Diluted) | (1.13) | (2.27) | (2.18) |
| Weighted Avg Shares | 30.08M | 30.08M | 31.52M |
| Weighted Avg Shares (Diluted) | 30.08M | 30.08M | 31.52M |
Evommune, Inc.
NYSE:EVMN
Intrinsic Alpha fair value
Locked
Current Price
$6.88
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.